Algert Global LLC Cuts Stock Position in Janux Therapeutics, Inc. $JANX

Key Points

• Algert Global LLC reduced its stock position in Janux Therapeutics by 37.4% in Q1, owning 40,660 shares worth approximately $1,098,000 after selling 24,301 shares during the period.
• Despite Algert's reduction, other institutional investors like GAMMA Investing LLC and US Bancorp DE significantly increased their holdings in Janux Therapeutics during the first quarter.
• Analysts have a generally positive outlook for Janux, with a consensus rating of "Buy" and an average price target of $86.90, indicating expectations of growth in the company's stock value.

Algert Global LLC reduced its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 37.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,660 shares of the company's stock after selling 24,301 shares during the quarter. Algert Global LLC owned about 0.07% of Janux Therapeutics worth $1,098,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JANX. GAMMA Investing LLC boosted its holdings in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after purchasing an additional 1,574 shares during the period. US Bancorp DE raised its holdings in Janux Therapeutics by 2,402.9% during the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after buying an additional 1,658 shares during the period. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after buying an additional 442 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics during the fourth quarter worth $59,000. Finally, FNY Investment Advisers LLC boosted its stake in Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after buying an additional 2,425 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

Janux Therapeutics stock traded down $0.03 during midday trading on Thursday, hitting $23.32. 52,095 shares of the company's stock were exchanged, compared to its average volume of 927,305. The company has a market cap of $1.40 billion, a PE ratio of -12.92 and a beta of 2.86. The firm has a 50-day moving average of $24.53 and a two-hundred day moving average of $27.41. Janux Therapeutics, Inc. has a 12 month low of $21.97 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on JANX shares. Piper Sandler initiated coverage on Janux Therapeutics in a research note on Monday, August 18th. They set an "overweight" rating and a $42.00 target price on the stock. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics has a consensus rating of "Buy" and a consensus price target of $86.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.